Briones-Garduño JC, Carrillo-Esper R, Guerrero-Avendaño G, Meneses-Calderón J, Pérez-Calatayud ?A, Castorena-de AR, Briones-Vega CG, Díaz LM

Language: Spanish
References: 8
Page: 70-72
PDF size: 158.54 Kb.

REFERENCES

1. Guallar MP, Meiriño R, Donat-Vargas C, Corral O, Jouvé N, Soriano V. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. Int J Infect Dis. 2020;97:290-292.

2. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813-1826.

3. Mahmoud DB, Shitu Z, Mostafa A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? J Genet Eng Biotechnol. 2020;18:35.

4. Espreafico Junior CR, do Nascimento Antonio MV, Imperador CHL, Chin CM, Longhin Bosquesi P. Remdesivir, nitazoxanida e ivermectina na COVID-19. J Med. 2020;1:74-80.

5. Meneses Calderón J, Figueroa Flores MDR, Paniagua Coria L, Briones Garduño JC, Meneses Figueroa J, Vargas Contretas MJ, et al. Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries. 2020;14:982-986. doi: 10.3855/jidc.13274.

6. Seifrad S. Pirfenidona: a novel hypothetical treatment for COVID-19. Medical Hypotheses. 2020;144:110005.

7. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;76:1615-1618.

8. Guérin C, Albert RK, Beitler J, Gattinoni L, Jaber S, Marini JJ, et al. Prone position in ARDS patients: why, when, how and for whom. Intensive Care Med. 2020;46:2385-2396.